Earnings call transcripts

Management framed 2026 as a buy-side-led reset, emphasizing cost discipline, enterprise expansion and a path to quarterly break-even in the second half.

Management framed the quarter as weather-disrupted and margin-pressured, while emphasizing five growth initiatives and cost savings amid weak housing demand.

Management framed 2025 as a strategic inflection from transactional insurance toward an AI-enabled model, with disciplined costs offsetting mix-driven revenue pressure.

Management framed the turnaround as strategically on track but slower than desired, with North America and running leading while Sportswear, China and EMEA lag.

Management framed 2025 as a manufacturing-control inflection point, while acknowledging a slower facility ramp and a more conservative 2026 outlook.

Management emphasized broad-based momentum but tempered optimism with second-half caution around pricing elasticity, pull-forward risk and Hyve ramp timing.

Management framed 2026 as an investment-led transition, with customer acquisition and assortment modernization offsetting near-term macro and tariff pressure.

Management framed the recapitalization as clearing the way to revive PAVmed’s diversified subsidiary model and relaunch its medical-device portfolio.

Management framed 2026 around several clinical catalysts, while emphasizing that NMRA 215’s unexpected rat findings delay its path to the clinic.

Management framed 2025 as a legacy-project reset, emphasizing surety-backed liquidity and asset sales while acknowledging disappointing results and a shift toward core work.

Management reframed 2026 around supply-chain scarcity: sharper pricing and share opportunities offset materially lower volume assumptions and broader demand risk.

Management framed 2026 as a conversion year, shifting a lean commercial team toward VA and Medicare while pursuing payer coverage during Medicare’s delayed decision process.